Management

Our leadership team has a strong track record in developing and commercializing drugs for the treatment of renal and metabolic disorders.

John Butler
President and Chief Executive Officer

John Butler

+ Read Bio

John P. Butler joined Akebia as a director in July 2013 and was appointed as the President and Chief Executive Officer of Akebia in August 2013. Prior to joining Akebia, from 2011 until 2013, Mr. Butler served as the Chief Executive Officer of Inspiration Biopharmaceuticals, Inc. ("Inspiration"). Mr. Butler led the transactions that resulted in the sale of Inspiration's hemophilia assets to Cangene Corporation and Baxter International in early 2013, for a total aggregate consideration that could exceed $1 billion. From 1997 to 2011, Mr. Butler held various positions at Genzyme Corporation, now Sanofi Genzyme, most recently serving as President of the company's rare genetic diseases business. From 2002 until 2010, Mr. Butler led Genzyme's renal division. Prior to his work at Genzyme, Mr. Butler held sales and marketing positions at Amgen and Hoffmann-La Roche. Mr. Butler currently serves on the Board of Directors of Zynerba Pharmaceuticals, Inc. Mr. Butler previously served on the Boards of Directors of Relypsa, Inc. and Keryx Biopharmaceuticals, Inc. and was the Chairman of Keryx's Board of Directors and Chairman of the Board of Trustees of the American Kidney Fund. He received a B.A. in chemistry from Manhattan College and an M.B.A. from Baruch College, City University of New York.

Jason Amello
Senior Vice President and Chief Financial Officer

Jason Amello

+ Read Bio

Jason A. Amello joined Akebia as Senior Vice President, Chief Financial Officer, and Treasurer in 2013. Prior to joining Akebia, Mr. Amello served as Executive Vice President, Chief Financial Officer, and Treasurer of Ziopharm Oncology, Inc., a biopharmaceutical company, from 2012 to 2013. From 2000 to 2011, Mr. Amello held various positions at Genzyme Corporation, now Sanofi Genzyme, most recently as Senior Vice President, Corporate Controller, and Chief Accounting Officer, and led the Strategic Financial Services group through which he served as a key advisor on all of Genzyme's mergers and acquisitions and other strategic transactions. Earlier in his career, Mr. Amello spent 10 years in the business advisory and assurance practice of Deloitte, serving in various roles of increasing responsibility through senior manager. Mr. Amello currently serves on the Board of Directors of the New England Baptist Hospital where he is the Chair of the Quality of Care Committee and a member of the Finance and Investment Committee. He also serves on the Board of Directors of Acer Therapeutics Inc. where he is a member of the Audit Committee. Mr. Amello holds a B.S. in accounting from Boston College and is a Certified Public Accountant in the Commonwealth of Massachusetts.

Michel Dahan
Senior Vice President and Chief Business Officer

Michel Dahan

+ Read Bio

Michel Dahan joined Akebia in 2013 and is Senior Vice President and Chief Business Officer. Prior to joining Akebia, from 2010 to 2013, Mr. Dahan held various positions at Inspiration Biopharmaceuticals, Inc. ("Inspiration") and he negotiated the successful sale of its hemophilia assets to Cangene Corporation and Baxter International in early 2013. At Inspiration, he most recently served as Vice President, Commercial Development and Strategic Planning and led the global marketing and commercial development in preparation for two global launches. Prior to that, from 2003 to 2010, Mr. Dahan served in various roles for Ipsen, most recently as International Product Director, working on global marketing and strategic planning for its hemophilia franchise, and as Strategic Planning Director. Previously, he worked in Global Business Development and Licensing for Ipsen. He began his career in the investment banking division BNP Paribas in 2002. He earned his graduate degree in business administration at HEC Paris (France), his maitrise in mathematics from University Paris VI (France) and completed an executive education program (PLD) at Harvard Business School.

Tamara Dillon
Senior Vice President of Human Resources

Tamara Dillon

+ Read Bio

Tamara Dillon joined Akebia as Vice President of Human Resources in August 2014. Prior to joining Akebia, Ms. Dillon served as Head of Human Resources, Global Discovery Chemistry at Novartis Institutes for BioMedical Research, where she was responsible for all aspects of human resources across five sites and four countries. Previously, she held several key roles at Genzyme, a Sanofi Company, including Senior Director Human Resources, Global Research and Development. In this global leadership role, Ms. Dillon worked closely with the senior management team to ensure that overall business strategies were translated into impactful and effective human resources programs. Ms. Dillon received a B.S. in natural resources from Cornell University's College of Agriculture and Life Sciences.

Nikki Hadas
Senior Vice President and General Counsel

Nikki Hadas

+ Read Bio

Nicole Hadas joined Akebia in 2013 and is Senior Vice President, General Counsel and Corporate Secretary. Prior to joining Akebia, Ms. Hadas was Vice President and General Counsel at OvaScience, Inc. in 2013. Previously, Ms. Hadas served as the Senior Vice President and General Counsel at Inspiration Biopharmaceuticals, Inc., where she managed the successful sale of its hemophilia assets to Cangene Corporation and Baxter International in early 2013. From 2001 to 2011, Ms. Hadas worked at Genzyme Corporation, now Sanofi Genzyme, most recently as Senior Corporate Counsel. Prior to Genzyme, she was an associate at Foley Hoag, representing biopharmaceutical companies and healthcare providers in a wide variety of matters. Ms. Hadas received a B.A. from the University of Michigan and a J.D. from Boston College Law School.

Rita Jain, M.D.
Senior Vice President, Chief Medical Officer

Rita Jain

+ Read Bio

Rita Jain, M.D. joined Akebia Therapeutics as Senior Vice President and Chief Medical Officer in May 2017. Prior to joining Akebia, Dr. Jain was the Vice President of Men's and Women's Health and Metabolic Development at AbbVie, Inc. From 2003 to 2016 she held positions of increasing responsibility, with over 10 years as either a Divisional Vice President or Vice President in Pharmaceutical Development at Abbott Laboratories, and after AbbVie's split from Abbott, at AbbVie. In addition to her work in Men's and Women's Health, and Metabolic Development, she also led activities in Pain, Respiratory, and Cystic Fibrosis Development. Before AbbVie, she held management positions in the Arthritis, Inflammation and Pain Group at Searle (acquired by Pharmacia and subsequently Pfizer). Prior to joining Searle, Dr. Jain was a faculty member at North Shore University Hospital in New York, with an academic appointment as Assistant Professor of Medicine, New York University School of Medicine. Dr. Jain received her B.S. in biology from LIU/CW Post and her M.D. from the State University of New York at Stony Brook School of Medicine. Dr. Jain completed her medical training in internal medicine at Staten Island University Hospital followed by a Fellowship in Rheumatology at North Shore University Hospital and a Clinical Research Fellowship at the University of Texas Southwestern Medical Center, Dallas.

Karen Tubridy, Pharm.D.
Senior Vice President, Chief Development Officer

Karen Tubridy

+ Read Bio

Karen Tubridy, Pharm.D. joined Akebia as Senior Vice President, Chief Development Officer in November 2016. Prior to joining Akebia, Ms. Tubridy served as Chief Development Officer at Eleven Biotherapeutics, Inc. from June 2013 to September 2016. Prior to joining Eleven Biotherapeutics, Ms. Tubridy served as Senior Vice President, Clinical Development and Medical Affairs of Inspiration Biopharmaceuticals, Inc. from 2011 to 2013. From January 2011 to November 2011, Ms. Tubridy served as Executive Director, Clinical Operations and Regulatory Affairs, Translational Medicine at Alexion Pharmaceuticals, or Alexion, and as Vice President of Clinical Operations and Regulatory Affairs of Taligen Therapeutics, which was acquired by Alexion, from April 2010 to January 2011. Prior to that, Ms. Tubridy served as Vice President of Clinical Operations, Hemophilia at Biogen Idec, Inc. from January 2007 through March 2010. Ms. Tubridy received a B.S. and a Pharm.D. from the Massachusetts College of Pharmacy and Health Sciences. Ms. Tubridy is a member of the Board of Trustees at Massachusetts College of Pharmacy and Health Sciences.